TNF and TNF receptor expression and insulin sensitivity in human omental and subcutaneous adipose tissue--influence of BMI and adipose distribution. 2006

Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
Centre for Diabetes & Endocrine Research, University of Queensland, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland, Australia 4102.

Tumour necrosis factor (TNF)alpha is implicated in the relationship between obesity and insulin resistance/ type 2 diabetes. In an effort to understand this association better we (i) profiled gene expression patterns of TNF, TNFR1 and TNFR2 and (ii) investigated the effects of TNF on glucose uptake in isolated adipocytes and adipose tissue explants from omental and subcutaneous depots from lean, overweight and obese individuals. TNF expression correlated with expression of TNFR2, but not TNFR1, and TNF and TNFR2 expression increased in obesity. TNFR1 expression was higher in omental than in subcutaneous adipocytes. Expression levels of TNF or either receptor did not differ between adipocytes from individuals with central and peripheral obesity. TNF only suppressed glucose uptake in insulin-stimulated subcutaneous tissue and this suppression was only observed in tissue from lean subjects. These data support a relationship between the TNF system and body mass index (BMI), but not fat distribution, and suggest depot specificity of the TNF effect on glucose uptake. Furthermore, adipose tissue from obese subjects already appears insulin 'resistant' and this may be a result of the increased TNF levels.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007333 Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003847 Deoxyglucose 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity. 2-Deoxy-D-glucose,2-Deoxyglucose,2-Desoxy-D-glucose,2 Deoxy D glucose,2 Deoxyglucose,2 Desoxy D glucose
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
February 2008, Journal of lipid research,
Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
January 2009, PloS one,
Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
February 2008, Diabetes research and clinical practice,
Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
May 2009, Metabolism: clinical and experimental,
Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
October 2010, The Journal of steroid biochemistry and molecular biology,
Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
January 2002, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity,
Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
March 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
March 2004, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity,
Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
May 2008, Acta paediatrica (Oslo, Norway : 1992),
Manuela Good, and Felicity M Newell, and Larisa M Haupt, and Jonathan P Whitehead, and Louise J Hutley, and Johannes B Prins
June 2020, JCI insight,
Copied contents to your clipboard!